Genovis reports interim results for January-June 2026
Net sales grew 19% in Q2, boosted by acquisition and strong genomics; underlying profitability strengthened.
See the latest news and media coverage for Genovis. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company specializing in protein analysis tools
genovis.comLast updated
In short: Genovis achieved strong sales growth in 2026, expanded its genomics platform through acquisitions, and secured major ADC licensing deals.
Net sales grew 19% in Q2, boosted by acquisition and strong genomics; underlying profitability strengthened.
The acquisition adds KPL's proprietary precision proteases for mass spectrometry-based protein analysis, strengthening Genovis' coverage in proteomics.
The meeting approved financial statements, re-elected board, authorized share issuance, and updated remuneration guidelines.
Net sales reached SEK 33,506 thousand. EBITDA improved to SEK 9,510 thousand. Launched LysCERATOR™ and SEQguard™. Signed ADC license deal.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least...
kr 20.95 SEK-0.05-0.24% ...
Genovis AB announces that Chief Financial Officer (CFO) Magnus Långberg has decided to leave the company to pursue a new opportunity outside the Group. Magnus...
Genovis' innovative products and technologies are used by scientists all over the world and the product formats streamline and improve workflows in biochemical analysis and...
Track Genovis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Genovis and other trending companies.